| abstract |
The present disclosure provides methods and compositions relating to the modification of immune effector cells to improve therapeutic efficacy. In some embodiments, the expression of one or more endogenous target genes has been reduced, or the function of one or more of the endogenous proteins has been reduced to enhance the effector function of immune cells. Provides immune effector cells. In some embodiments, immune effector cells further modified by introducing a transgene that imparts antigen specificity, such as an extrinsic T cell receptor (TCR) or chimeric antigen receptor (CAR), are provided. .. Also provided are methods of treating cell proliferation disorders such as cancer using the modified immune effector cells described herein. |